KYMR Form 4: Chief Legal Officer Granted RSUs and $43.30 Strike Option

Rhea-AI Filing Summary

Kymera Therapeutics insider grant to Chief Legal Officer The filing shows that Brian Adams, Chief Legal Officer of Kymera Therapeutics (KYMR), was granted 52,500 restricted stock units (RSUs) and a stock option covering 105,000 shares on September 3, 2025. The RSUs vest in four equal annual installments beginning September 3, 2026, subject to continued employment. The option has an exercise price of $43.30, vests 25% on September 3, 2026, with the remainder in 36 equal monthly installments, and expires on September 2, 2035. Following the grants, Mr. Adams directly beneficially owns 52,500 shares from the RSUs and 105,000 option shares reported.

Positive

• 52,500 RSUs granted to the Chief Legal Officer with a clear four-year annual vesting schedule
• 105,000 share stock option granted with a specified $43.30 exercise price and defined vesting and expiration dates
• Direct beneficial ownership amounts reported for both RSUs and options, providing transparent disclosure

Negative

• None.

Insights

Securities Analyst

TL;DR: The Form 4 reports routine equity compensation for a senior officer: RSUs and an option with multi-year vesting.

The reported grants to the Chief Legal Officer are standard long-term compensation, consisting of 52,500 RSUs vesting over four years and a $43.30 strike option for 105,000 shares with a ten-year term and typical cliff-plus-monthly vesting. These awards increase the officer's direct beneficial ownership and create potential future share issuance upon vesting or exercise. The filing contains clear vesting schedules and exercise price, allowing investors to model potential dilution timing and strike-related proceeds if exercises occur.

Corporate Governance Expert

TL;DR: Governance disclosure is complete for these grants: names, amounts, vesting, exercise price, and ownership are provided.

The Form 4 provides full Section 16 disclosure for the officer-level equity grants, including explicit vesting schedules and the option expiration date. From a governance perspective, the filing documents compliance with reporting obligations and supplies the facts necessary for stakeholders to assess timing of potential insider acquisitions of company stock. No additional governance actions or departures are reported in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Adams Brian

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/03/2025		A		52,500(1)	A	$0	52,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$43.3	09/03/2025		A		105,000		(2)	09/02/2035	Common Stock	105,000	$0	105,000	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following September 3, 2025, subject to the reporting person's continued employment through each vesting date.

2. Twenty-five percent (25%) of the shares underlying this stock option shall vest on September 3, 2026, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date.

	/s/ Bruce Jacobs, as Attorney-in-Fact	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity did Brian Adams (KYMR) receive on 09/03/2025?

He was granted 52,500 restricted stock units (RSUs) and a 105,000-share stock option on 09/03/2025.

What are the vesting terms for the RSUs reported on Kymera's Form 4?

The RSUs vest in four equal annual installments beginning September 3, 2026, subject to continued employment.

What is the exercise price and term of the stock option granted to the Chief Legal Officer?

The option has an exercise price of $43.30, vests 25% on September 3, 2026 with the remainder in 36 monthly installments, and expires on September 2, 2035.

How many shares does the reporting person beneficially own following the transaction?

The Form 4 reports 52,500 shares from RSUs and 105,000 shares underlying the option as beneficially owned following the transaction.

Who signed the Form 4 on behalf of the reporting person?

The form is signed /s/ Bruce Jacobs, as Attorney-in-Fact dated 09/03/2025.